Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.3
5.5
Journals
Biomolecules
Special Issues
Hydrogen Sulfide-Based Therapeutics
share announcement

Hydrogen Sulfide-Based Therapeutics

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Chemical Biology".

Deadline for manuscript submissions: closed (31 May 2020) | Viewed by 9026

Special Issue Editors

Prof. Dr. Harry van Goor

E-Mail Website
Guest Editor
Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands
Interests: oxidative stress; biomarkers; thiosulfate; hydrogen sulfide
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Jaap A. Joles

E-Mail Website
Guest Editor
Department of Nephrology and Hypertension, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands
Interests: cardiorenal syndrome; uremic animal models; regenerative nephrology; renal hypoxia; gasotransmitters; developmental renal programming; diabetic kidney disease; portable dialysis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hydrogen sulfide (H2S) is an endogenously produced gaseous signaling molecule that exerts various effects in mammals. It is the third gasotransmitter, in addition to NO and CO. Over the last decade, it has been shown that H2S has beneficial effects in the cardiovascular system, including vasodilation, antioxidant effects, and the suppression of inflammation. Various H2S donors have now been described, and some of these have progressed into clinical trials for a variety of indications, such as the inhibition of inflammation, calciphylaxis, and cardiovascular protection. Hydrogen sulphide research is rapidly progressing and is moving in a variety of directions. Biomolecules is devoting a Special Issue to highlight the importance of H2S in drug development and therapy.

The Issue on “Hydrogen Sulfide-Based Therapeutics” welcomes articles related to therapeutic approaches of H2S in various animal models, the pharmacological role  of H2S production in biological systems, (patho-)physiological signalling in human and experimental disease, interactions of hydrogen sulphide with reactive oxygen species in the regulation of biological functions in health and disease, drug development related to H2S, and H2S metabolites as biomarkers in health and disease.

Prof. Dr. Harry van Goor
Prof. Dr. Jaap A. Joles
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Hydrogen sulfide
  • Diabetes
  • Aging
  • Cardiovascular
  • Acute and chronic kidney disease
  • Therapeutics
  • Pharmacology

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 5906 KiB  
Article
The Effect of a Fast-Releasing Hydrogen Sulfide Donor on Vascularization of Subcutaneous Scaffolds in Immunocompetent and Immunocompromised Mice
by Alexandra M. Smink, Avid Najdahmadi, Michael Alexander, Shiri Li, Samuel Rodriquez, Harry van Goor, Jan-Luuk Hillebrands, Elliot Botvinick, Jonathan R. T. Lakey and Paul de Vos
Biomolecules 2020, 10(5), 722; https://0-doi-org.brum.beds.ac.uk/10.3390/biom10050722 - 06 May 2020
Cited by 4 | Viewed by 5682
Abstract
Islet transplantation into subcutaneous polymer scaffolds has shown to successfully induce normoglycemia in type 1 diabetes models. Vascularization of these scaffolds is imperative for optimal control of glucose levels. We studied the effect of the vascular stimulator hydrogen sulfide (H2S) on [...] Read more.
Islet transplantation into subcutaneous polymer scaffolds has shown to successfully induce normoglycemia in type 1 diabetes models. Vascularization of these scaffolds is imperative for optimal control of glucose levels. We studied the effect of the vascular stimulator hydrogen sulfide (H2S) on the degree of vascularization of a scaffold and the role of the immune system in this process. Scaffolds were subcutaneously implanted in immunocompetent C57BL/6 and immunocompromised nude mice. Mice received twice-daily intraperitoneal injections of the fast-releasing H2S donor sodium hydrosulfide (NaHS, 25 or 50 μmol/kg) or saline for 28 days. After 63 days the vascular network was analyzed by histology and gene expression. Here we showed that the vascularization of a subcutaneous scaffold in nude mice was significantly impaired by H2S treatment. Both the CD31 gene and protein expression were reduced in these scaffolds compared to the saline-treated controls. In C57BL/6 mice, the opposite was found, the vascularization of the scaffold was significantly increased by H2S. The mRNA expression of the angiogenesis marker CD105 was significantly increased compared to the controls as well as the number of CD31 positive blood vessels. In conclusion, the immune system plays an important role in the H2S mediated effect on vascularization of subcutaneous scaffolds. Full article
(This article belongs to the Special Issue Hydrogen Sulfide-Based Therapeutics)
►▼ Show Figures

Figure 1

14 pages, 4396 KiB  
Article
Sodium Thiosulfate in the Pregnant Dahl Salt-Sensitive Rat, a Model of Preeclampsia
by Fieke Terstappen, Sinéad M. Clarke, Jaap A. Joles, Courtney A Ross, Michael R. Garrett, Magdalena Minnion, Martin Feelisch, Harry van Goor, Jennifer M. Sasser and A. Titia Lely
Biomolecules 2020, 10(2), 302; https://0-doi-org.brum.beds.ac.uk/10.3390/biom10020302 - 14 Feb 2020
Cited by 13 | Viewed by 2973
Abstract
Aberrant production of hydrogen sulfide (H2S) has been linked to preeclampsia. We hypothesized that sodium thiosulfate (STS), a H2S donor, reduces hypertension and proteinuria, and diminishes fetal growth restriction in the Dahl salt-sensitive (S) rat, a spontaneous model of [...] Read more.
Aberrant production of hydrogen sulfide (H2S) has been linked to preeclampsia. We hypothesized that sodium thiosulfate (STS), a H2S donor, reduces hypertension and proteinuria, and diminishes fetal growth restriction in the Dahl salt-sensitive (S) rat, a spontaneous model of superimposed preeclampsia. In addition to a control group (n = 13), two groups received STS via drinking water at a dose of 2 g (n = 9) or 3 g per kg body weight per day (n = 8) from gestational day (GD) 10 to 20. Uterine artery resistance index was measured (GD18), urinary protein excretion rate was determined (GD19), and blood pressure and fetal outcomes were evaluated (GD20). At 2 g, STS had no effect on preeclamptic symptoms or fetal outcome. At 3 g, STS reduced maternal hypertension (121.8 ± 3.0 vs. 136.3 ± 2.9), but increased proteinuria (89 ± 15 vs. 56 ± 5 mg/24 h), and relative kidney weight (0.86 ± 0.04 vs. 0.73 ± 0.02%). Fetal/placental weight ratio was reduced (3.83 ± 0.07 vs. 4.31 ± 0.08) without affecting litter size. No differences in uterine artery flow or renal histological damage were noted across treatment groups. While these data suggest a promising antihypertensive effect that could imply prolongation of preeclamptic pregnancies, the unfavorable effects on proteinuria, kidney weight, and fetal/placental weight ratio implies that clinical implementation of STS is contra-indicated until safety for mother and child can be verified. Full article
(This article belongs to the Special Issue Hydrogen Sulfide-Based Therapeutics)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop